Which of the following is a GLP-1 agonist?
The correct answer here would be a drug that acts as a GLP-1 agonist. Common examples I recall are Exenatide, Liraglutide, Semaglutide, and others like Dulaglutide. These are used in the management of type 2 diabetes. Let me think about the options. Since the question didn't list the options, I need to assume typical ones. For example, if the options include Exenatide, that's correct. If they have Metformin, that's a biguanide. If there's Sitagliptin, that's a DPP-4 inhibitor, not a GLP-1 agonist. So the wrong options would be other classes of diabetes medications.
Now, why the other options are incorrect. If an option is a DPP-4 inhibitor, like Sitagliptin, it works by inhibiting the enzyme that breaks down GLP-1, so it's different from being an agonist. If there's a SGLT2 inhibitor like Canagliflozin, that's another class. If an option is a sulfonylurea like Glipizide, that's a different mechanism entirely. Also, insulin itself is not a GLP-1 agonist, but a hormone.
Clinical pearls: Remember that GLP-1 agonists are associated with weight loss and lower risk of hypoglycemia compared to other antidiabetics. They're often used in patients who need weight management. The mnemonic might be "GLP-1 agonists: Exenatide, Liraglutide, Semaglutide" to remember the names. Also, their injectable form is a key differentiator from oral medications like Metformin or Sitagliptin.
So, putting it all together, the correct answer would be the GLP-1 agonist drug, and the explanation should cover the mechanism, why others are wrong, and the clinical takeaways.
**Core Concept**
GLP-1 (Glucagon-Like Peptide-1) agonists are incretin mimetics that enhance glucose-dependent insulin secretion, suppress glucagon release, and delay gastric emptying. They are used in type 2 diabetes management and obesity treatment.
**Why the Correct Answer is Right**
The correct option (e.g., **Exenatide**, **Liraglutide**, or **Semaglutide**) binds to GLP-1 receptors on pancreatic beta cells, activating adenylate cyclase and increasing cAMP to stimulate insulin release. They also reduce appetite via central and gastrointestinal mechanisms, contributing to weight loss. These agents are administered subcutaneously and are contraindicated in pancreatitis.
**Why Each Wrong Option is Incorrect**
**Option A:** *Sitagliptin* is a DPP-4 inhibitor, which blocks degradation of endogenous GLP-1, not a direct agonist.
**Option B